Zaid Naima

Zaid Naima is a San Francisco-based solo angel investor with a stated focus on diagnostics, and on this directory’s data the profile is genuinely thin: there is no website, no Twitter or Crunchbase footprint, no public stage profile, no public check-size disclosure, no AI focus indicated, and no published thesis statement. The LinkedIn profile is the only public surface, which is not unusual for a solo angel but means founders evaluating Zaid as a potential check-writer should treat the data here as a starting point and verify everything (active deal history, recent checks, current capital position, areas of conviction) directly through outreach or through a warm reference. The geography signal is the strongest data point: a San Francisco-based angel will typically have access to the Bay Area founder and operator network and is most useful for founders who are building in or near that ecosystem, since solo angels at any check size are valuable mostly for their network rather than for capital scale. The diagnostics focus is the second-strongest signal: solo angels who specialize tend to do so because they have domain expertise (clinician background, prior diagnostics-company operating experience, or scientific training) or because they have built a thesis through their own deal history, and either way it suggests Zaid is more likely to engage with a diagnostics-specific pitch than with a generalist healthcare deck. Founders who should consider approaching Zaid are pre-seed and seed-stage diagnostics founders in the Bay Area or with a Bay Area presence, particularly those who want to fill out a small angel round with domain-aware checks rather than to find a lead. Founders should not approach Zaid for institutional-sized leads, for therapeutics or devices outside diagnostics, or for stages beyond seed, since solo angels at the early stage rarely have the capital base to support multiple follow-ons. The entry path is direct LinkedIn outreach with a tight one-paragraph pitch, ideally preceded by a warm intro from a mutual connection in the diagnostics or San Francisco operator network; solo angels are generally responsive to short, specific, well-targeted messages and unresponsive to mass outbound. When you reach out, lead with the diagnostic technology, the clinical evidence to date, and the specific reason you want this angel on your cap table (network, domain experience, prior similar deal); generic asks for capital without a clear reason are easy to ignore. Caveats: with this little public data, founders should expect to do their own diligence on Zaid before sending detailed materials, including verifying current check-writing activity, ideal check size, and any conflicts with adjacent diagnostics companies; an angel who has not invested in twelve months is a different proposition from one writing a check a quarter, and founders cannot tell which is which from this profile alone.